Sanofi has disclosed a substantial open-market purchase of shares in Attovia Therapeutics, Inc. (ATTO), according to a Form 4 filed with the SEC. The filing shows Sanofi bought 300,000 shares on August 6, 2026 at a price of $17.00 per share, a transaction valued at $5,100,000.00.
Following the purchase, Sanofi’s stake in Attovia stands at 1,082,855 shares, held indirectly through an entity or trust structure rather than in Sanofi’s own name. Indirect ownership of this kind is common among corporate and institutional insiders and typically reflects shares held via an affiliated fund, subsidiary, or investment vehicle rather than a personal brokerage account.
The transaction is classified by our tracking system as a straightforward open market buy, meaning Sanofi used its own capital to acquire the shares directly on the market rather than receiving them through options, restricted stock vesting, or other compensation-related mechanisms. That distinction matters to filing-watchers because open market purchases are generally viewed as a clearer signal of insider conviction, since the buyer is voluntarily committing capital at the prevailing market price.
Part of a Broader Pattern at Attovia
This is not an isolated filing for Attovia Therapeutics. The company has seen a string of insider buying activity disclosed around the same period, including a $10 million purchase by Frazier Life Sciences and a $3.4 million purchase by Redmile Group. Readers can find more detail on the Redmile Group transaction and the broader cluster of buying activity in our earlier coverage, ATTO: Redmile Group Buys $3.4M in Attovia Amid Cluster Buying.
When multiple insiders or affiliated institutions purchase shares of the same company within a short window, it is often referred to as cluster buying. Academic research on insider trading disclosures has found that clustered buying activity has historically correlated with periods of stock outperformance relative to the broader market, though such findings describe statistical tendencies across large datasets rather than predictions about any single company or filing.
Sanofi’s involvement adds a notable name to the list of parties accumulating shares in Attovia Therapeutics around this timeframe. As with all Form 4 disclosures, the filing represents a factual record of a completed transaction reported to the SEC, and readers interested in the underlying details can consult the original filing for the full context of Sanofi’s reported holdings and transaction history with the company.
→ See all ATTO coverage on WhoIsBuyingNow
Source: original SEC Form 4 filing.